Thomas Hwang is the founder of the Cancer Innovation and Regulation Initiative at the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, and a resident physician in urological surgery at Brigham and Women’s Hospital/Harvard Medical School. His research focuses on the regulation, reimbursement, and clinical development of new medicines and health technologies. His work has contributed to important policy and regulatory reforms in the United States and Europe, and. has been published in Science, New England Journal of Medicine, JAMA, Lancet, and Lancet Oncology. He received his M.D. from Harvard Medical School and his A.B. from Harvard College.
- 2022, Consolidation in Drug Markets: Impact on Prices and Access, $75,000